Abacavir
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Tenofovir disoproxil fumarate ABC 740 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg x 1 | No significant change |
||
| Abacavir AZT, ZDV 671 | Green: Administer standard doses | Administer standard doses | Inconsistent effect across all dosing regimens; No effect on AUC with clinical abacavir dose of 300mg BID |
200 mg TID, 300 mg BID | No significant change |
||
| Abacavir AZT, ZDV 670 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg x 1 dose | Zidovudine Cmax decreased 20%; AUC no significant change |
||
| Abacavir 3TC 669 | Green: Administer standard doses | Administer standard doses | No significant change |
150 mg x 1 dose | Lamivudine Cmax decreased 35%; AUC decreased 15% |
||
| Abacavir Ethanol 668 | Green: Administer standard doses | Administer standard doses | Abacavir AUC increased 41%; half-life: increased 26%; Cmax increased 15%; T1 / 2 increased |
0.7 g / kg body weight | No significant change |
||
| Abacavir MMF, MPA 667 | Green: Administer standard doses | Administer standard doses | No significant change |
500 mg BID x 16 weeks | |||
| Abacavir Methadone 666 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of methadone | Potential for decreased methadone effects (e.g., withdrawal) |
No significant change |
40 mg once daily; 90 mg once daily | Methadone clearance increased 22% |
If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose |
| Abacavir |

